An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
| العنوان: | An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access |
|---|---|
| المؤلفون: | Natasha B. Leighl, Doreen A. Ezeife, Sharon Nirmalakumar, Bishal Gyawali |
| المصدر: | American Society of Clinical Oncology Educational Book. :e1-e12 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Drug, medicine.medical_specialty, media_common.quotation_subject, MEDLINE, Antineoplastic Agents, 03 medical and health sciences, 0302 clinical medicine, Promotion (rank), Neoplasms, Health care, medicine, Humans, 030212 general & internal medicine, Dosing, Intensive care medicine, Biosimilar Pharmaceuticals, media_common, Leg, business.industry, Cancer, Biosimilar, General Medicine, medicine.disease, Harm, 030220 oncology & carcinogenesis, Arm, Drugs, Essential, business |
| الوصف: | Increasing cancer drug prices present global challenges to treatment access and cancer outcomes. Substantial variability exists in drug pricing across countries. In countries without universal health care, patients are responsible for treatment costs. Low- or middle-income countries are heavily impacted, with limited patient access to novel cancer treatments. Financial toxicity is seen across cancer types, countries, and health care systems. Those at highest risk include younger patients, new immigrants, visible minority groups, and those without private health coverage. Currently, cancer drug pricing does not correlate with value or clinical benefit. Value-based pricing of oncology drugs may incentivize development of higher-value medicines and eliminate excess spending on drugs that yield little benefit. Generics and biosimilars in oncology can also improve affordability and patient access, offering dramatic reductions in drug spending while maintaining patient benefit. Oncologists can promote value-based care by following evidence-based clinical guidelines that avoid low-value treatments. Researchers can also engage in value-based research that critically explores optimal cancer drug dosing, schedules, and treatment duration and defines patient populations most likely to benefit (e.g., through biomarker selection). Cancer Groundshot proposes that we improve outcomes for today's patients with cancer, including broader global access for high-value treatments, promotion of affordable cancer control strategies, and reduction of cancer morbidity and mortality through low-cost prevention and screening initiatives. Moving forward, major oncology societies recommend promoting uniform global access to essential cancer medicines and avoiding financial harm for patients as key principles in addressing the affordability of cancer drugs. |
| تدمد: | 1548-8756 1548-8748 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a726e78780cb208a75fdbcbd8b98a758 https://doi.org/10.1200/edbk_100028 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....a726e78780cb208a75fdbcbd8b98a758 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15488756 15488748 |
|---|